|Day Low/High||1.45 / 1.52|
|52 Wk Low/High||1.16 / 10.35|
Verastem could be a buy after a test of the 200-day line around $5.50.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
Verastem Inc., T2 Biosystems Inc. and Resonant Inc. have great long-term growth prospects.
The market is down across the board as one might expect given escalating trade tensions today. However, losses are slight in this context in the first hour of trading. Given the option expiration date, volatility could pick up later in the day. Some...
After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.